Generic Finacea Availability
FINACEA (azelaic acid - gel; topical)
Manufacturer: BHP DERMATOLOGY
Approval date: December 24, 2002
Strength(s): 15% [RLD]
Has a generic version of Finacea been approved?
No. There is currently no therapeutically equivalent version of Finacea available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Finacea. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Composition with azelaic acid
Issued: March 18, 2003
Inventor(s): Patrick; Franke & Clemens; Günther & Jutta; Riedl
Assignee(s): Schering Aktiengesellschaft
The invention relates to a pharmaceutical composition having the following constituents: azelaic acid, polyacrylic acid, triacylglyceride, propylene glycol, polysorbate, soya lecithin, water and salts. The composition is a hydrogel which is suited for the treatment of rosacea, presbyderma, melasma or skin irritations.Patent expiration dates:
- November 18, 2018
- November 18, 2018
- Finacea Consumer Information (Drugs.com)
- Finacea Plus gel Consumer Information (Wolters Kluwer)
- Finacea gel Consumer Information (Wolters Kluwer)
- Finacea Consumer Information (Cerner Multum)
- Finacea Plus Consumer Information (Cerner Multum)
- Finacea Plus Topical Advanced Consumer Information (Micromedex)
- Finacea Topical Advanced Consumer Information (Micromedex)
- Azelaic acid cream Consumer Information (Wolters Kluwer)
- Azelaic acid gel Consumer Information (Wolters Kluwer)
- Azelaic acid topical Consumer Information (Cerner Multum)
- Azelaic acid Topical Advanced Consumer Information (Micromedex)
- Azelaic Acid AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|